-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 UoEtmgnKxjpoB1Ie+rSrStiINwXH3mbH1mjFhRQJH6/oZEF+bZTuAU5eg3HAud44
 Ev/Hu8nPFlYjB0TJ+52SCw==

<SEC-DOCUMENT>0001178913-09-001301.txt : 20090602
<SEC-HEADER>0001178913-09-001301.hdr.sgml : 20090602
<ACCEPTANCE-DATETIME>20090602060136
ACCESSION NUMBER:		0001178913-09-001301
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090602
FILED AS OF DATE:		20090602
DATE AS OF CHANGE:		20090602

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		09866649

	BUSINESS ADDRESS:	
		STREET 1:		72 PINCHAS ROSEN ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			69512
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		72 PINCHAS ROSEN ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			69512
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk96842.htm
<TEXT>
<HTML>
<HEAD>
     <!-- Created by EDGAR Ease Plus (EDGAR Ease+) -->
     <!-- Project:        \\Backup\edgar filing\Compugen Ltd\96842\a96842.eep              -->
     <!-- Control Number: 96842                                                            -->
     <!-- Rev Number:     1                                                                -->
     <!-- Client Name:    Compugen Ltd                                                     -->
     <!-- Project Name:   6-K                                                              -->
     <!-- Firm Name:      Zadok-Keinan Ltd                                                 -->
     <TITLE>6-K</TITLE>
</HEAD>
<BODY>

<!-- MARKER FORMAT-SHEET="Scotch Rule Top-TNR" FSL="Workstation" -->
<HR ALIGN=LEFT WIDTH=100% SIZE=4 NOSHADE STYLE="margin-top: -5px">
<HR ALIGN=LEFT WIDTH=100% SIZE=1 NOSHADE STYLE="margin-top: -10px">

<!-- MARKER FORMAT-SHEET="Head Major Center Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=4>FORM 6-K </FONT><BR>
<FONT FACE="Times New Roman, Times, Serif" SIZE=4>SECURITIES AND EXCHANGE COMMISSION </FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Washington, D.C. 20549 </FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold 1-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Report of Foreign
Private Issuer </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Workstation" -->
<P align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant
to rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 </FONT><BR>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>for the month of June
2009 </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Center Underline-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="5"><U><B>Compugen Ltd.</B></U> </FONT><BR>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>(Translation of registrant&#146;s name in English) </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Center Underline-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><U>72 Pinchas Rosen
Street, Tel-Aviv 69512, Israel </U></FONT><BR>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>(Address of principal
executive offices) </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Indicate by check mark whether the
registrant files or will file annual reports under cover Form 20-F or Form 40-F. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Form 20-F <FONT size="3" face="Wingdings">x
</font>  Form 40-F <FONT size="3" face="Wingdings">o
</font></FONT></P>


<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On June 2, 2009 Compugen Ltd. (the
&#147;Registrant&#148;) issued a Press Release, filed as Exhibit 1 to this Report on Form
6-K, which is hereby incorporated by reference herein. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><U>SIGNATURE</U> </FONT> </H1>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized. </FONT></P>

<!-- MARKER FORMAT-SHEET="Signature (Single)" FSL="Workstation" -->
<TABLE WIDTH=100% CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=40%><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=10%><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=50%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Compugen Ltd.<BR>(Registrant)<BR>
<BR>By: /s/ Ms. Dikla Czaczkes Axselbrad<BR>&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;<BR>
Ms. Dikla Czaczkes Axselbrad<BR>Chief Financial Officer<BR>Date: June 2, 2009</FONT></TD>
</TR>
</TABLE>
<BR>

<p align=center>
<font size=2></font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px">
<HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exhibit_1.htm
<TEXT>
<HTML>
<HEAD>
     <!-- Created by EDGAR Ease Plus (EDGAR Ease+) -->
     <!-- Project:        \\Backup\edgar filing\Compugen Ltd\96842\a96842.eep              -->
     <!-- Control Number: 96842                                                            -->
     <!-- Rev Number:     1                                                                -->
     <!-- Client Name:    Compugen Ltd                                                     -->
     <!-- Project Name:   6-K                                                              -->
     <!-- Firm Name:      Zadok-Keinan Ltd                                                 -->
     <TITLE>6-K</TITLE>
</HEAD>
<BODY>
<!-- MARKER FORMAT-SHEET="Scotch Rule Top-TNR" FSL="Workstation" -->
<HR ALIGN=LEFT WIDTH=100% SIZE=4 NOSHADE STYLE="margin-top: -5px">
<HR ALIGN=LEFT WIDTH=100% SIZE=1 NOSHADE STYLE="margin-top: -10px">


<!-- MARKER FORMAT-SHEET="Head Major Left Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=right><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><U><B>Exhibit 1</B></U> </FONT> </H1>

<IMG SRC="compugenb.jpg"><BR><BR>

<!-- MARKER FORMAT-SHEET="Head Left-TNR" FSL="Workstation" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>For Release </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Sub 1 Left-TNR" FSL="Workstation" -->
<P ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Compugen Appoints Dr. Anat Cohen-Dayag and Martin Gerstel as Co-CEOs</B> </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Tel Aviv, Israel, June 2, 2009 &#150;
Compugen (NASDAQ:CGEN) announced today the appointment of Anat Cohen-Dayag, Ph.D. and
Martin Gerstel as co-CEOs of the company. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Flush Lv 0- TNR" FSL="Workstation" -->
     <P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Dr. Cohen-Dayag joined Compugen in 2002, and has held the positions of director of
          diagnostics, vice president for diagnostic biomarkers &amp; drug targets, and
          most recently, vice president of R&amp;D. Prior to joining Compugen, she was
          head of R&amp;D and a member of the executive management at Mindsense Biosystems
          Ltd. Dr. Cohen-Dayag holds a B.S. in Biology from Ben-Gurion University, and an
          M.S. in chemical immunology and a Ph.D. in cellular biology from the Weizmann
          Institute of Science. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Flush Lv 0- TNR" FSL="Workstation" -->
     <P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Mr. Gerstel joined Compugen in 1997 as chairman of the board, and served in that
          role until January of this year when he was appointed president and CEO. Prior
          to joining Compugen he was co-chairman and CEO of ALZA Corporation, a California
          based pharmaceutical company which he helped found, and a director of the
          Pharmaceutical Research and Manufacturers of America (PhRMA). Currently he
          serves as a director of various public and private companies including Evogene
          Ltd. and Itamar Medical Ltd, and various educational and civic organizations
          including the Weizmann Institute of Science, the Hebrew University, the US
          Foundation for the National Medals of Science and Technology and the Israel-U.S.
          BiNational Industrial Research and Development (BIRD) Foundation. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Dov Hershberg, chairman of Compugen
stated, &#147;Compugen is very fortunate to have the combined technical, financial and
leadership qualities of Anat and Martin to lead us as we continue our development.
Together they have all the relevant skills and experience to assure our continued and
accelerating progress and have clearly demonstrated the ability to work very successfully
together as a team. Although both will have full CEO responsibilities with respect to all
corporate functions, they have agreed that to maximize the value of their efforts, Anat
will take the lead in overseeing the Company&#146;s internal operations including all
research and development activities, management of the Company&#146;s existing
collaborations, IP and all administrative and support functions, and Martin the lead with
respect to the Company&#146;s external activities including finance and investor
relations, and the establishment of additional collaborations and alliances.&#148; </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Martin Gerstel stated, &#147;Having
spent more than a decade creating a powerful infrastructure for predictive drug and
diagnostic product discovery, 10 initial discovery platforms and a growing inventory of
validated product candidates, the Company is now focusing more and more of its efforts on
collaborations and other commercialization and corporate development activities.
Therefore, I am very pleased that this change will allow me to dedicate more of my efforts
to overseeing these activities and external finance. In addition, there is no doubt in my
mind that key decisions regarding the overall strategy and future direction of the Company
will greatly benefit from having our combined input on an equal basis.&#148; </FONT></P>

<p align=center>
<font size=2></font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px">
<HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<page>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Anat Cohen-Dayag stated, &#147;During
the past few years, the exceptional talent, experience and potential of the Compugen team
have been increasingly demonstrated through the accelerating announcements of new
platforms and product candidates in an increasing number of important medical areas. It
has been an honor and privilege for me to participate in the establishment of these
capabilities as both a team member and a member of management. Looking to the future, I am
extremely enthusiastic to share with Martin the CEO role and am confident that working
together, we will provide the necessary guidance and oversight for our company to meet its
very aggressive medical and financial goals.&#148; </FONT></P>


<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>About Compugen</B> <BR>Compugen is a leading drug and
diagnostic product candidate discovery company. Unlike traditional high throughput trial
and error experimental based discovery, Compugen&#146;s discovery efforts are based on
<I>in-silico</I> (by computer) prediction and selection utilizing a growing number of
field focused proprietary discovery platforms accurately modeling biological processes at
the molecular level. The resulting product candidates are then validated through <I>in
vitro</I> and <I>in vivo</I> experimental studies and out-licensed for further development
and commercialization under various forms of revenue sharing agreements. Compugen&#146;s
current collaborations include Biosite, Medarex, Inc., Merck &amp; Co., Inc., Merck
Serono, Ortho-Clinical Diagnostics (a Johnson &amp; Johnson company), Roche, Siemens
Healthcare Diagnostics, Inc., and Teva Pharmaceutical Industries. In 2002, Compugen
established an affiliate, Evogene Ltd. <U>www.evogene.com</U> (TASE: EVGN.TA), to utilize
certain of the Company&#146;s <I>in-silico</I> predictive discovery capabilities in
agricultural biotechnology. For additional information, please visit Compugen&#146;s
corporate Web site at <U>www.cgen.com</U>. </FONT> </P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>This press release may contain
&#147;forward-looking statements&#148; within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements include words such as &#147;may&#148;,
&#147;expects&#148;, &#147;anticipates&#148;, &#147;believes&#148;, and
&#147;intends&#148;, and describe opinions about future events. These forward-looking
statements involve known and unknown risks and uncertainties that may cause the actual
results, performance or achievements of Compugen to be materially different from any
future results, performance or achievements expressed or implied by such forward-looking
statements. Some of these risks are: changes in relationships with collaborators; the
impact of competitive products and technological changes; risks relating to the
development of new products; and the ability to implement technological improvements.
These and other factors are identified and more fully explained under the heading
&#147;Risk Factors&#148; in Compugen&#146;s annual reports filed with the Securities and
Exchange Commission. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Left-TNR" FSL="Workstation" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B><I>Company contact:</I></B> </FONT> </P>

<!-- MARKER FORMAT-SHEET="Head Left-TNR" FSL="Workstation" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Marjie Hadad </FONT><BR>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>Global Media Liaison </FONT><BR>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>Compugen Ltd. </FONT><BR>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>Email: marjie@cgen.com </FONT><BR>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>Tel: +972-54-536-5220 </FONT></P>

<p align=center>
<font size=2>2</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px">
<HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>compugenb.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 compugenb.jpg
M_]C_X``02D9)1@`!``$`E@"6``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``0"`P,#`@0#`P,$!`0$!@H&!@4%!@P)"0<*#PT/#PX-
M#@X0$A<4$!$6$0X.%!P5%A@9&AL:$!0='QT:'Q<:&AD!!`0$!@4&#`8&#!D1
M#A$9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9
M&1D9&1D9&?_$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`%$`U@,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/OZ@`H`;O7.WOV'K0!Q/Q+\>ZOX5U&"RTSX<>*O$YD0N\VE
M10^7%Z`M(ZY/TH`\;^(`@\:>(7UG7_@=\:FN&0($M-?DM8D4=ECANU0?ES0!
MB2^%O#B0,TGP-^.BHHRQ?Q==!0/<F^P!0!RGC>UM+;3H?^$'^!OQ%U.^ED"M
M'J/Q(GMT`[;=EZS,Q.,`"@#Z`_9S^#^A^'K6P\;ZUX.&F>,I;8QNMSKEWJQL
M48Y,<<MPS%6(QNV@#.1DB@#V*@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`"@`H`*`/"OCC\3M+U3[?X//A_XOVB6ESL?5/"NG21&;8>0DP&=A/=<
M9QUQ0!Y>+GPX/^6W[57T^U7G^-`#EG\.$<2_M4_^!=Y_C0!Y_P#$B]UC5/[0
M\/\`_"J/VBO$WAZX'EG^T_%<\*W2?[<)C;C/8DT`;7[%?P9\":G\9[76;SX`
M^,O!TOAH+J-I>:]K+7$#SJV$`C,2Y93\X.>"H-`'W30`4`%`!0`4`%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`$=U&TMM)&DK0LZE5D3&5)'49XXH`^4
M?&]W'X2\4W?AW6OVEOC+'?6+!9%M_"K7$?(##;)'9,K#!'()H`R/^$KT?_HY
MOXV_^$;/_P#(%`%;6=>\.ZEHUYIE[^TK\;IK:\A>&:(>#[A"Z,,$!A8@KD$C
M((H`^=SH7@@$JNC_`+3CA3C<@AP?<90'\P*`/3?V5/'?AGX1_$<ZM;>%?C[=
MVNIQK97?]NV4=Q;P1EU/G%8T\SY.3A>2">"<"@#]!].NH+VP@O;60207$:R1
MNO1E(R#0!-0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`&;
MXNL=4U'P]=66BZT^C7TJ8AOT@28PMV.QQM;Z&@#YN^(WQ%O/`/BN?PSXP_:M
MATG5;94:2VG\'1YVL,J00A!!'<$]".H-`&%_POC0_P#H\>Q_\(Y/_C=`',>/
M_'G@_P`97%I+J'[;6HV+V@94_LC1'L@P."=^Q1NZ<9Z<T`>.M\5?#Z2.B_&W
M]HR3:Q&^+3[5D;'=3]JY![&@#TS]E3]HKPQX5^)EIIM[XZ^,7B*SUZ>.R:#Q
M+HUMY,,KL%23S5N&=`"><`Y!Z<4`??M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`'@7QI^*MO\`\)6MKX+_`&A?A-X;CLD,%[9:S)%<
M3B<,<\B==N!QM(SG-`'(?\+1\6?]'7_`K_P'C_\`DF@!5^*'BLG!_:O^!6.X
M^SQ]/_`F@#PKXG?'K5;SQK>,G[7[:=]G(MS%X?\`"TALV*\%T)<[@?[P.#0!
MH?`KQUXP^('Q8T/POH/[6_B76KFZN5DDLE\,O$)(D.^3<Y;"#:",GUH`_1"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`R=5\4^&=+OFLM2\
M1Z39W*`%H+B\CC=0>A*D@\T`>=_$CQQXODUI8_`7BOX5Q::JX9];U-VED;'.
M%CX`_$Y]J`.`9?&VXDS?LWY/)SO_`,*`.2^(WQ*7P&\,?B?7/V=+>6?E(;:S
MN+E\>I6-3@>YH`\Z\;_'2TUB&WCT'XK?!;PPT1)DEL_"D]PTOH#YT+``>PS[
MT`:7PB3XR_%&\FM/`'QL^'NK_9P3)/'X&1((SZ&1K4+N]LYH`^P?@=X'U+P=
MX3AB\2:Q9:[X@D&;O4K?2K>Q4YYV(D*+\@/3=DGK[``[B@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@#SGXC>,/B1IOB)[/P;X)\,ZSIZ(-UWJ/
MB;[$^_\`B41B"3@>I(^E`'DNI>$M4U'49]0U+]E[X,WMY=2&2:YN?$D<DDC'
MJ69K$DGW)H`KS>"6BA>67]E3X'QQQJ6=V\0P@*!U)/V#I0!X?\2]?T/4KR!?
M!.E?LJ^$H(AB9+BXM=2DF;_>DME"K[!<^_:@#'\-6/C/7M>M=%T#6?V6]1U.
M_D\JWM+/1K!Y97ZX`$'I0!],?L__`+-^K(PU/XR:-\,+D@,JZ)H?A"QCC]`T
MEQY>\]<[5"]!DGD4`?1/AO1=(\/:/#I6A:79:98VXQ':V4"PQ)]%4`"@"_0`
M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`?)4GPE>25Y)/V/-&
M9W8LS-XTC)8DY)/R^M`"?\*B_P"K.M$_\+./_P")H`JZW\([H:-=&Q_9`\,P
M7(B;RY;[Q>CP(<<,Z@`E1W&10!X[#X"\9R,L<?P7_9G>1B%"KJH)8]@!]KZF
M@#["_96^#6C?#_P[!KVI^!_!VA^,KV$I>OX;MG2&%"<B)&=W8XXW,",D>@%`
M'G/[57[;G@KX4^([KPEX:T:7Q;XALSLN!#.L5I:OG&QI`&+..ZJOMD&@#RC1
M_P#@H7XRT'Q:FG_$KX0+86QVR216DLL%U#$PR'"3##\<@94'U%`'U3\7_P!H
M/X<?#CX/Z;\1M:U-Y]-URWCN-*MK10UQ?[T#J$4D=B,DD`=S0!\GZ]_P4<\1
MR7KWF@?"*V31X9!&TM[?R.S$\X+)&%0D=N?QH`^B_P!D7]J;P;\<],U1(M.N
MO#NM:';_`&N]TZZD$J>3T,L<@`W*#@'(4@D<<YH`\'T__@HX9O%L6FS?"ZW@
MT][L0-?+K#R%8]^"X1;?+''(4=>E`&?XO_X*.ZM:^/98M#^&5JWA^VG,;)J%
MV\=[,@/7@;8F(_A(;'K0!I?&/_@HHECJEO:_#?P$+RU,4<TE[KDCQ;]P!*I$
MO.!R-Y;!P>,=0#V*X_:NT]?V)E^/4'A=GN!*EF=&FN?+#W!E$;A9=IRH!9@=
MO(&.*`/(/#G_``4>MKJPU634OA+=0W-K;^99V]GJ?G"9\\^8YB7RD`Y+8;Z4
M`=1^R-^W"_Q4^+MGX!\4>"[719]7+BQO;.],B;PI81NK*.2`?F!Z]J`*'Q[_
M`&^C\/OC)XB\$:9\,XM9@T&\-F+YM7,)F=0`_P`@A;&'W`<G.!0!U'[4/[8E
M_P#!N/P;;7/PZAU'4_$NC)JUU:G5#"++<<",'RF+\AADA>G2@#I?A=^U/I.J
M_LLWGQQ\>:"OA;2XKN2TM+*&Z^U2WK+PHCRB99FW`#H`I)(`.`#PG2?^"C>J
M7/C))KCX3^5X6A_X^S;7C37D*$X$@;8J<#^$@9/&X4`=-\%?V]-5^(WQE\/>
M`]/^$L5N-=U&.T^UG62QBB+9>39Y`R50,VW(Z8S0!WG[6W[9_@SX->*)/!^D
MZ'<>*_$MOL-S:P7"PP6N[^"27#'S,$':%/7DB@#R70_^"AOB#2/%<-C\1?A`
M^EV4Q21OL]S(ES#"V<2".5`)./=<X-`'LO[8G[6%A\%M#\&:GHGAJ+Q5#XSM
MI+VW;[<;4+`JQLK_`.K8G<)1C('0T`>/3_\`!1H-\/)]2A^&.S76O/LT-H;]
MWMHH]@;S)9?*7EB2%C4$G8Y)7Y=P!ZW^P+^U'>_'R\US0]>\,V^D:OHT:70D
ML9&:":%FV]&Y5@?<@@]L4`?2M`'SA\9O`?AK3/'=U+'\)?BEXG;4F:]EOM`U
ML+;B1V)9`KW494@]@N,$8]@#E/\`A&?#W_1N_P`<_P#P=Q__`"=0`V;PKX:F
MB>&7]G/XXO'(I5D;6HB&!X((^W=*`//_`(6?!^X'[0VC02_LI6&@>&UU,2PZ
MKJFJ$7,,*G<CM"+AE9QA<@;AF@#[@^).I7>C?#K7M7LHS)=:?I]Q<PJHR2Z1
MLR\#W%`'X[_LD6%CXM_:O\#P^*-4MXH+W7(KR[N+YP$G=6,VQB>"9'4)[EP.
M]`'U9^T5\6?V2/&OQWOX/$OP]\3>,/$,,R:3'>:4ZM#=NIVHL1$P#?,2`<<F
M@#R#_@J:'T?XZ:#X#LX'L]`\)^'+2VTJR8Y\F,@@Y/.X_*%SD_=H`O>//$O@
MOPS_`,$M?"/@?3-1TR\\1^+-5>^OX+:=&F@,<[L6D7[RX58DY_#(H`SOV&X=
M5\)?!KXS_%=T^SZ7;>&GT.WFD0[9[J9U.U#T.T`9]-ZT`<Y_P3:\+V?B;]KK
MPPFI1K)9Z(DVK2JPR,PQDH3_`,#*T`</XH^T_$W]IF]CA5/.\5>)##&%''[R
M?:/T-`'I/_!3?4]-D_:=G\.:,MNEAX0TNUTB-((@@4JFY@<>A;%`'7?M5'_A
M!O\`@GQ\&_AW'*L<^ONVOWD1^\05+(?I^^_2@#(_8L\2?#[P-^S7\9O$NOZS
MIR>(]2TPZ-IVF2RKY\JRQ.H*1GYF&]QDC@!><4`<U_P39T";5?VK_#^IXD6T
M\+PSZO=R!>$2.)@`3T&2P%`'G&EZG:>+/CY!K?BF_2RL]:\0"[U"[ER4B1Y]
M[D^P!_`4`>A?\%%?B#H_Q#_:AU?4_#6JP:IH6D6=OI6GW=N<QND:;GVG^)?-
M>3##@CD9%`'1?MLV&H>#O@!\"_AZ5EM[2'0IM8GC^8+)=3LI8GL2H)QW`<^M
M`$_P,\>?#7P%^P!\1M/DU.RF\=^-IVTQ=."DW'D[556/&`BJTK@YQGCK@4`5
M?^"7&BSW/[15]XG@LQ<R>$=`O=0@4C(\\IY:#TYW-0!Y7\"M%U_XG?M#:+8Q
M>)X=,U[6]0>\&M7RAUCN`KS>8PZ$EEX]R*`/5?C5X'T/Q9\6)-.^('[5VBZ_
MXJM672@5T*_NOFW';"LD,11L,Y'!."2.H(H`H_\`!1R7^Q_BUX8^&BWYNT^&
M_A+3=#DDVE0TJPAV8#W5HS^G:@#J/CY:Z;X&_P""9_PI\,1VD=OJOC34I-=N
M"8_GE1%<[R>N0LT`'L:`/6/^")7AB2/0/'OC211Y=U=6VEP-GH8D:20?^1HO
MRH`^[:`.<^)W@RQ\;^'/['O=6UW2D$BRBYT349;*<$=O,C(.#GD'B@#SW_AG
M#P__`-%)^+/_`(6%Y_\`%4`'_#.'A_\`Z*3\6?\`PL+S_P"*H`CTG]F'P!:?
M$'0_&MYKOC;6=8\.2^=83ZQK\]WY)ZD#>3\I[CO0![/)&KAE<!E88*D<8H`^
M4?BA^P!\(?$WB&YU71=2UGPW]KF,SVEFRO`I)RP16'RCT&<#M0!V/[/G['GP
M?^$_BF#Q/I]E>ZSK5FV^UN]5E#BV;D;D0`*&YZD$CJ,&@#H/VG/V;OAQ\<;>
MWF\4VMS;:O91^5;:K92;)HTR3L(/#+DYP1QV(H`\9\'_`/!.OX5Z;J8N-<\4
M>(M7A4@_9PR0!L=B5&<?3%`'N_Q'^`_@3Q5\!H_A!;6TV@>&(3&8[?2F",H1
MMV,MDG)Y).2222<F@#D/@)^R1\._A)JNMZEX:U+6I+O6],DTMY;J5&:&-R"Q
M0A1AN!S0!@?"O]AOX3^`_B)HGC'3=3\07-YH5TEY!%<SH8S(ARI("CH<'\*`
M(_B3^PQ\+O&_CW6/%VLZ_P")C?ZU=/=3A+A`H9CT'R].U`'RE_P5HUNS;]H7
M2?!NGLJV7@_1(+.-`1\A;YL?4*%H`]/_`&=_V)?`_P`3_P!F+P9XJU?4=3T+
M7M1@DNI[FS(83Q/(3'N5N`0F,$8X-`'U?^SA\!?A]\%?"EUHOA33Y)9-1Q]N
MOKUO,FNL`@!CT"@$_*!CF@#Q]O\`@G[\&&\>MKC7VO?V8TIE_L43J(AEL[=^
M-VSMC.<=Z`)O$7[`_P`&]6\576MM>ZY:_:KDW!L[:6-((P6R$5=O"@<?2@#@
M/^"F'Q(\`:-XDTOX7_$7X27VL:?IUHEWH^KVNH_99%#*$<(=IX!4!E.0=JG'
M`H`^5OBOXF^`"?!BVT?X8^"M;M/$VIW,<VI:AKDPF-I$F3Y4##&=S;23M!PI
M'>@#[3_X)*?!W5_`?PVUCQIXITJXT[4_%<B);VMTFR1+5`2K,IY&YF)P>P%`
M%GXH_P#!/WX2>)O$MQJV@ZIJWAB.ZD,C6%GLDMXR>HC5A\HSVS@=L"@#L/V?
MOV-?A!\*?%=KXHLX-0UK6;')M[C4Y0Z0L?XUC``##L3G%`&9\7_V)/AG\1OB
M/K7C77]?\2C4M;G,\WE3H$3@*JJ-O0*%`SZ4`='\>?V5O`?Q7TSPKIFN:KK=
MI8^#[`V%A;64JJH4A`6.5/S$1H/PH`[;]FWX1>&O@I\.CX.\+37<UFUU)>/+
M=L&D=WP#D@`<!0/PH`[^@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`^1_VD_\`
MDM6N?2'_`-%B@#Z5^$'_`"2SP]_V#X?_`$`4`='0`4`%`'S?_P`%.?\`DWZ+
J_K_7_P!!-`'P?_P3B_Y._P##7_;;_P!!-`'[`4`%`!0`4`%`!0`4`?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
